Medication info
Ozatam Plus Tablet 50/12.5, 100/25 milligrams

Ozatam Plus Tablet 50/12.5, 100/25 milligrams

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mgHydrochlorothiazide›25mg
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablet
Packaging
50/12.5mg: 30 tablets/bottle, 300 tablets/bottle 100/25mg: 30 tablets/bottle
Approval status
Active

MFDS item code 200600478 · Notified 2006.01.27 · Insurance code 643502010,643502020

Summary

Main use
Treatment of hypertension uncontrolled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is seen approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy: This drug may replace combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose should be administered when creatinine clearance is 30 mL/min or higher. Use of loop diuretics rather than thiazide-type drugs is preferable in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Because the initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment, 25 mg, cannot be administered using this drug, administration to these patients is not recommended.
Child dose
Pediatric patients (under 18 years): There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension uncontrolled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension whose blood pressure is inadequately controlled with monotherapy.

How to take

Adult dose

○ Adults The usual dose of this drug is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is seen approximately 3 weeks after starting treatment. This drug may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this drug only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy: This drug may replace combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the hydrochlorothiazide dose without reducing the overall blood pressure-lowering effect. Thereafter, continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment The usual dose should be administered when creatinine clearance is 30 mL/min or higher. Use of loop diuretics rather than thiazide-type drugs is preferable in patients with more severe renal impairment; therefore, administration to these patients is not recommended. ○ Patients with hepatic impairment Because the initial dose of losartan potassium for patients with hepatic impairment requiring dose adjustment, 25 mg, cannot be administered using this drug, administration to these patients is not recommended.

Child dose

Pediatric patients (under 18 years): There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if used during pregnancy, especially during the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication or its components, severe kidney or liver disease, and certain electrolyte imbalances should not take this medication. Particular caution is required when using this medication in patients with low blood pressure or impaired kidney function, liver disease, hyperuricemia or gout, and elderly patients. This medication may affect serum electrolyte levels, so regular blood tests to monitor potassium, sodium, and other levels are necessary. Due to the hydrochlorothiazide component, the skin may become sensitive to sunlight, so sun exposure should be avoided and skin protection should be considered during treatment. Dizziness or drowsiness may occur while taking this medication, so caution is needed when driving or operating machinery. This medication may interact with other drugs, so consultation with a physician is required, especially when taking potassium supplements, antihypertensives, diuretics, non-steroidal anti-inflammatory drugs, etc. Women who are pregnant or planning to become pregnant should consult their physician, and nursing mothers should also consult a healthcare professional before taking this medication. It is not recommended to use this medication in children and adolescents as safety and efficacy have not been established. If any unusual symptoms occur during treatment, immediately inform a physician and seek advice.

Side effects

  • Abdominal pain
  • edema
  • palpitations
  • lower back pain
  • dizziness
  • cough
  • sinusitis
  • upper respiratory infection
  • rash
  • angioedema
Show 125 more
  • skin exfoliation
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • hypotension
  • myocardial infarction
  • secondary atrioventricular block
  • anorexia
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorder
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory impairment
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • neural hypersensitivity
  • panic disorder
  • sensory abnormalities
  • peripheral neuropathy
  • sleep disturbance
  • drowsiness
  • tremor
  • dyspnea
  • nasal bleeding
  • nasal congestion
  • discomfort in the throat
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitive reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • decreased vision
  • taste abnormalities
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • seizures
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • fever
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle cramps
  • restlessness
  • renal failure
  • kidney dysfunction
  • interstitial nephritis
  • mucocutaneous syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal exudate
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a tightly sealed container that blocks light. Also, it is important to maintain a temperature between 1 to 30 degrees Celsius when storing the medication. Storing it this way preserves the drug's effectiveness and safety.

Appearance and packaging

Appearance

Yellow oval film-coated tablet

Package unit

50/12.5mg: 30 tablets/bottle, 300 tablets/bottle 100/25mg: 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.